Akari Therapeutics PLC (AKTX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$7.83

+0.09 (+1.10%)

Market Cap: $21.23M

Last updated: Nov 06, 2026 at 4:10 PM ET

Earnings

Performance (10Y)

Beat Rate

64%(14/22)

Avg Surprise

-44.78%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-2.38

Range$-2.38 - $-2.38

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$0.00n/a

60d ago$0.00n/a

30d ago$0.00n/a

7d ago$0.00n/a

Current$-2.38

Revenue Consensus

Range$0 - $0

2 analysts

Period ending Dec 31, 2026

EPS Consensus$-2.83

Range$-2.83 - $-2.83

1 analysts

Revenue Consensus

Range$0 - $0

2 analysts

Last 12 of 36 reported quarters and 2 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-2.83	$-2.83 - $-2.83	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$-2.38	$-2.38 - $-2.38	-	-	1	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 13, 2026Reported Aug 13	$-2.69	$-1.04	$-1.04 - $-1.04	-158.47%	Miss	1	1 0 30d	+31.4%
Mar 31, 2026Mar 26 Reported Apr 7, 2026Reported Apr 7	$-9.72	$-0.66	$-0.66 - $-0.66	-1372.91%	Miss	1	No revisions (30d)	-5016.4%
Dec 31, 2025Dec 25 Reported Dec 31, 2025Reported Dec 31	$N/A	$-2.40	$-2.40 - $-2.40	N/A	Beat	1	No revisions (30d)	-
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-1.06	N/A	-	+75.91%	Beat	1	No revisions (30d)	-32.1%
Jun 30, 2025Jun 25 Reported Aug 13, 2025Reported Aug 13	$-3.92	$-4.80	$-4.80 - $-4.80	+18.33%	Beat	1	No revisions (30d)	-373.7%
Mar 31, 2025Mar 25 Reported Apr 14, 2025Reported Apr 14	$-0.19	N/A	-	+81.00%	Beat	-	-	+92.1%
Sep 30, 2024Sep 24 Reported Nov 18, 2024Reported Nov 18	$-9.59	N/A	-	N/A	Beat	-	-	-
Jun 30, 2024Jun 24 Reported Aug 18, 2024Reported Aug 18	$-0.80	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-
Mar 31, 2024Mar 24 Reported May 14, 2024Reported May 14	$-0.83	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-934.4%
Dec 31, 2023Dec 23 Reported Mar 29, 2024Reported Mar 29	$-2.40	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-2900.0%
Sep 30, 2023Sep 23 Reported Oct 3, 2023Reported Oct 3	$0.00	N/A	-	+100.00%	Beat	0	No revisions (30d)	+100.0%
Jun 30, 2023Jun 23 Reported Jul 19, 2023Reported Jul 19	$0.00	N/A	-	+100.00%	Beat	1	No revisions (30d)	+100.0%

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	-1.31x	FCF Yield	-76.51%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-140.10%	ROIC	-155.70%
Financial Health
Debt/Equity	0.04x	Interest Coverage	-32.35x
Current Ratio	0.60x	Quick Ratio	0.60x
Trading Statistics
Beta	1.47	Avg Volume	50.00K
52-Week High	$29.32	52-Week Low	$3.02

Technical Indicators Dashboard

Moving Averages

SMA 10$8.25

SMA 20$8.38

SMA 50$9.28

SMA 200$9.00

EMA 10$8.25

EMA 20$8.43

EMA 50$8.84

EMA 200$12.15

MACD

Line: -0.25Signal: -0.24Hist: -0.01

ADX

ADX: 10.9+DI: 18.2-DI: 18.3

Aroon & PSAR

Aroon Up44.0

Aroon Down36.0

PSAR$9.95

Bollinger Bands

Upper Band$9.70

Lower Band$7.05

%B Position3171%(Upper)

Band Width0.30

RSI (14-Day)

Neutral

45.7

Momentum Oscillators

Stoch %K33.0

Stoch %D39.2

Williams %R-79.1

ROC (10d)-4.7%

Momentum-0.39

CCI (20d)-98.3

MFI (14d)36.9

Volatility Measures

ATR (14d)$1.11(14.2%)

StdDev (20d)0.66

Hist Vol169.0%(High)

Volume Flow

VWAP$7.83

OBV15.6M

AD Line803554904078.4B

CMF (20d)-0.156

Volume Metrics

Avg Vol (20d)48.1K

Vol Ratio1.1x

VWMA (20d)$8.49

Pivot Points

R3$10.07

R2$9.55

R1$8.65

Pivot Point$8.13

S1$7.22

S2$6.70

S3$5.80

Advanced Oscillators

TSI-5.86

Ultimate Osc34.8

KST-96.29

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$25,998	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$1,000	N/A	N/A	N/A	$12,999	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$-1,000	N/A	N/A	N/A	$-12,999	N/A	N/A

Operating Expenses	$4.60M	$15.76M	$3.23M	$7.40M	$3.12M	$3.52M	$4.29M	$2.93M	$7.45M	$5.98M	$5.09M	$2.51M
R&D	$2.08M	$1.46M	$1.09M	$249,000	$667,000	$813,000	$1.25M	$143,000	$3.31M	$2.28M	$5.08M	$314,000
SG&A	$2.52M	$2.17M	$2.14M	$1.98M	$2.45M	$2.71M	$3.05M	$1.71M	$2.24M	$3,710	$2.58M	$2.82M
Operating Income	$-4,602,000	$-15,758,000	$-3,227,000	$-7,404,000	$-3,119,000	$-3,525,000	$-4,295,000	$-2,927,000	$-7,449,000	$-5,989,000	$-5,090,000	$-2,507,000

Interest Income	$0	$0	$0	$1,000	$0	$0	$1,000	$3,000	$2,000	$2	$7,000	$16,000
Interest Expense	$80,000	$61,000	$723,000	$120,273	$50,000	$55,000	$124,000	$69,000	$51,000	$0	$0	$0
Income Before Tax	$-4,807,000	$-15,314,000	$-5,213,000	$-7,488,000	$-1,895,000	$-3,705,000	$-3,772,000	$-2,895,000	$-7,558,000	$-5,566,000	$-4,138,000	$-2,871,000
Income Tax Expense	$0	$-859,000	$85,000	$-1,088,000	$0	$0	$0	$0	$0	$1	$0	$0

Net Income	$-4,807,000	$-14,455,000	$-5,298,000	$-6,400,000	$-1,895,000	$-3,705,000	$-3,772,000	$-2,895,000	$-7,558,000	$-5,566,000	$-4,138,000	$-2,871,000

EBITDA	$-4,727,000	$-15,253,000	$-4,490,000	$-7,367,000	$-1,845,000	$-3,650,000	N/A	$-2,826,000	$-7,507,000	$-5,553,000	$-4,137,000	$-2,870,000
EBIT	$-4,727,000	$-15,253,000	$-4,490,000	$-7,367,000	$-3,119,000	$-3,648,000	$-4,295,000	$-2,949,001	$-7,449,000	$-5,566,000	$-4,138,000	$-2,871,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about AKTX

News

Akari Therapeutics, Plc (AKTX) Seasonal returns chart

This Yahoo Finance article presents the seasonal returns chart for Akari Therapeutics, Plc (AKTX). It shows the average monthly price return for AKTX from 2016 to 2026...

Yahoo Finance UK•Oct 31, 2026 8:00 PM ET10/31/26•Somewhat-Bullish

Akari Therapeutics shareholders approve increase in shares for 2023 equity plan

Akari Therapeutics (NASDAQ:AKTX) shareholders have approved a significant increase in the number of ordinary shares available for grant under the company’s 2023 equity incentive plan...

Investing.com•Oct 31, 2026 2:25 PM ET10/31/26•Somewhat-Bullish

Form 8K Akari Therapeutics PLC ADR For: 30 October By Investing.com

This article announces that Akari Therapeutics PLC (AKTX) filed a Form 8K for the period ending October 30, 2026. The Form 8K is a crucial document used by public companies to announce major events that shareholders...

Investing.com Canada•Oct 30, 2026 12:52 PM ET10/30/26•Neutral

Akari Therapeutics Files Registration for 1.8 Million ADS Under 2023 Equity Incentive Plan

Akari Therapeutics, Plc has filed a Form S-8 registration statement with the U.S. SEC to register an additional 144,000,000,000 ordinary shares, corresponding to 1,800,000 American Depositary Shares (ADS)...

Kalkine Media•Oct 30, 2026 10:07 AM ET10/30/26•Neutral

Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit

Akari Therapeutics will present its novel RNA-splicing antibody drug conjugate (ADC) payload strategy at the 3rd Annual ADC Payload Summit. The presentation will discuss how this approach...

GlobeNewswire•Oct 30, 2026 5:05 AM ET10/30/26•Neutral

AKTX Valuation and Fair Value

P/FCF: -1.3x
PEG: 0.0x
P/B: 0.8x

See GNG's fair value

AKTX Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: -155.7%
ROE: -140.1%
FCF yield: -76.5%

AKTX Competitors

Company	Ticker
CervoMed Inc.	CRVO
Seres Therapeutics Inc	MCRB
MIRA Pharmaceuticals, Inc. Common Stock	MIRA
Entero Therapeutics, Inc.	ENTO
China Pharma Holdings Inc	CPHI
Immutep Ltd ADR	IMMP
NextCure Inc	NXTC
TherapeuticsMD Inc	TXMD

Sector: Healthcare

AKTX Bull Case vs Bear Case

Bear case

AKTX beat EPS estimates in 37.5% of its last 8 reported quarters.

AKTX Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -271.2%
EPS estimate (fiscal period ending Sep 30, 2026): $-2.38
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

AKTX Earnings Date

AKTX reports Nov 11, 2026. The date is estimated.

See insider activity

Frequently Asked Questions About AKTX

When does AKTX report earnings?

Akari Therapeutics PLC (AKTX) is expected to report earnings on Nov 11, 2026.

Does AKTX pay dividends?

Akari Therapeutics PLC (AKTX) does not currently pay a regular dividend.

What is AKTX's market cap?

Akari Therapeutics PLC (AKTX) has a market capitalization of $21.23M with a current stock price of $7.83.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In